Form 4 Filing for Fady Ibraham Malik

Fady Ibraham Malik, EVP Research & Development at CYTOKINETICS INC (CYTK), reported a series of transactions on June 9, 2026. Malik acquired 3500 shares of Common Stock at a price of $7.80 per share, increasing their post-transaction holdings to 157,402 shares. Concurrently, Malik disposed of 3500 shares of Common Stock at $67.98 per share, resulting in 153,902 shares remaining. Additionally, Malik exercised a Non-Qualified Stock Option, disposing of 3500 shares of the underlying Common Stock. The option had an exercise price of $7.80, and following the transaction, 44,386 options remained outstanding.